Farxiga
Product Images NDC 55154-6932

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Farxiga (NDC 55154-6932). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 4

This appears to be a chart or graph that shows the percentage of patients who experienced an event over time (measured in months) for a treatment called FARXIGA versus a placebo. The number of patients at risk for each group is provided. However, without more information on what the "event" being measured is and what FARXIGA is used to treat, it's difficult to provide a more specific description.*

FDA Label Image

Figure 5

FDA Label Image

Figure 6a

This appears to be a statistical comparison between the efficacy of the drug FARXIGA and a placebo. The efficacy is represented as a percentage of patients with an event over time in months. The graph shows a decrease in the number of events in patients taking FARXIGA compared to those taking the placebo. The hazard ratio and p-value are also provided for statistical analysis.*

FDA Label Image

Figure 6b

This appears to be a statistical comparison between the drug FARXIGA and a placebo in a group of patients over a 24-month period. The table shows the percentage of patients with an event, the hazard ratio with a 95% confidence interval, and the P-value. The graph shows the number of patients at risk over time for each treatment group. The drug FARXIGA appears to have a lower percentage of patients with an event compared to the placebo.*

FDA Label Image

Figure 6c

The text describes the results of a study comparing the efficacy of FARXIGA versus placebo in treating a medical condition. It includes a graph showing the percentage of patients with an event over time, as well as statistics on the hazard ratio and P-value. The study was conducted over a 24-month period and included over 2000 patients in each group.*

FDA Label Image

Figure 7

FDA Label Image

Dapagliflozin Chemical Structure (Dapagliflozin Struct)

FDA Label Image

Farxiga Figure 1 (Farxiga Fig1)

This appears to be a graph showing the relationship between urinary glucose levels (measured in grams) and the dose of Dapagliflozin (measured in milligrams) for both healthy subjects and those with T20M. Two fitted lines are also shown for each group. However, without additional context or information, it is difficult to provide a more specific description or interpretation of the data.*

FDA Label Image

Figure 8

This is a clinical trial result table showing the number of patients, event percentage, and comparison of FARXIGA versus placebo over 32 months from randomization. There is no information on the nature of the event or the study's goal.*

FDA Label Image

Image 01

FDA Label Image

Image 02

The text is describing a graph that shows the adjusted mean change from baseline HbA1c (%) levels for randomized subjects who completed the Short-Term Period without rescue. It also includes a table that shows the values for adjusted mean change from baseline at various weeks for the combination of PLACEBO + METFORMIN and FARXGA 10 MG + METFORMIN treatments.*

FDA Label Image

Image 03

This is a prescription medication called Farxiga containing dapagliflozin tablets. The packet contains approximately 30 tablets with a strength of 5mg. The packet includes a modification guide to manage the disease and prevent medical errors. The document also includes a warning to keep the medication out of reach. Some parts of the text are not readable.*

FDA Label Image

Image 04

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.